The Critical Role of 'Hyper-Targeting' in Rare Disease Drug Development with Dan Donovan

» This is a free bonus issue for all subscribers. Only paid subscribers access our regular monthly newsletters with exclusive analysis. Upgrade to a paid subscription here.

---

In a recent episode of our podcast, The Life Science Rundown, The FDA Group's Nick Capman spoke with Dan Donovan, a medical device consultant with over 30 years of experience in the device industry, to understand the key parts of risk management for device firms today.

Apple | Spotify | YouTube | Web + Others

They discuss:

• The critical role of patient advocates and caregivers in conducting successful studies and applications for bringing a rare disease drug to market.

• The resource challenges faced in the field of rare diseases and drug development.

• The potential for individuals to contribute to the rare disease sector, specifically through the Five Voices program.

• Successful and unsuccessful attempts to bring rare disease drugs to market, including the success story of Sarepta in getting the first drug for Duchenne muscular dystrophy approved and the failure of a company to enroll patients for their trial due to poor community relations.

• The unique approach required for rare disease drug development, termed "hyper-targeting," which emphasizes focusing resources on specific rare disease communities and expert centers—and ongoing engagement with the community from the development phase through to commercialization.

• The role of rareLife Solutions is providing in guiding to companies interested in the hyper-targeting approach.

• The personal aspect of working in the field of rare diseases, including the importance of passion for the work and the need to channel it positively for the benefit of others.

Dan is the visionary behind rareLife Solutions and oneVoice, and has spent his career innovating in the medical and pharmaceutical industries.

Introduced to the world of rare diseases through his involvement as an investor and Chief Business Officer at Cancer Prevention Pharmaceuticals (CPP), he observed the fragmented nature of rare disease communities, which inspired him to establish oneVoice, a platform for guided communities specific to rare diseases.

Earlier in his career, Dan founded Envision Pharma, where he served as President and developed Datavision, a leader in medical publications technology. The company was acquired by United BioSource Corporation (UBC), where he served as Senior Vice President Strategy and Market Development.

You can follow and connect with Dan on LinkedIn here.

---

Not a paid subscriber yet?

Here’s what you’re missing:

• 🔒 FDA Revives Its Proposed Quality Metrics for Pharma and Clarifies Device Cybersecurity Recommendations + Warning Letter Breakdown

• 🔒 Revisions to Q9(R1) Quality Risk Management, Getting "Recall Ready" + Warning Letter Breakdown

• 🔒 Reviewing RMPs Against FDA's Drug Shortage Guidance, Inside FDA's Device VIP + Warning Letter Breakdown

• 🔒 Reporting CMC Post-Approval Changes, Proactively Addressing the Root Causes of Medical Device Recalls + Warning Letter Breakdown

• 🔒 Alternative cGMP Compliance Methods for Combo Products, Device Production and Quality System Software Assurance + Warning Letter Breakdown

• 🔒 Revised Compliance Guides for PAIs and GMP Drug Inspections, New Guidances On Device Post-Approval Studies, Postmarket Surveillance + Warning Letter Breakdown

• 🔒 Implementing ICH Q14’s Enhanced Approach to Analytical Method Development, FDA's Proposed Framework for Human Factor Info in Device Submissions + Warning Letter Breakdown

• 🔒 FDA Finalizes Guidance on REMS Format and Content, Preparing for Expanded Device Inspection Authority + Warning Letter Breakdown

• 🔒 “The Compliance Issue” Addressing the Top-Cited CFRs to Pharma and Device Firms + Warning Letter Breakdown

• 🔒 Applying FDA's Final ICH Q13 Continuous Manufacturing Guidance, Preparing for October's eSTAR Requirement + Warning Letter Breakdown

• 🔒 FDA's Draft Guidance on OTC Drug Submissions Content/Format, PCCPs for AI/ML Devices + Warning Letter Breakdown

Upgrade here to unlock all of these issues and new ones »

---

The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates.

Need expert help planning and executing compliance projects or connecting with a quality and compliance professional? Get in touch with us. If we haven’t worked together yet, watch our explainer video below or head to our company introduction page to see if we could help you execute your projects now or in the future.

Our service areas:

Quality Assurance | Regulatory Affairs | Clinical Operations | Commissioning, Qualification, and Validation | Manufacturing and Engineering | Expert Witness

Our engagement models:

Consulting Projects | Staff Augmentation | FTE Recruitment | Functional Service Program

Our podcast:

Apple | Spotify | YouTube | Web + Others